XORTX Therapeutics Dirección

Dirección controles de criterios 3/4

El CEO de XORTX Therapeutics es Allen Davidoff , nombrado en Jan 2018, tiene una permanencia de 6.83 años. compensación anual total es $321.96K, compuesta por 79.2% salario y 20.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.37% de las acciones de la empresa, por valor de €90.99K. La antigüedad media del equipo directivo y de la junta directiva es de 2.9 años y 4.1 años, respectivamente.

Información clave

Allen Davidoff

Chief Executive Officer (CEO)

US$322.0k

Compensación total

Porcentaje del salario del CEO	79.2%
Permanencia del CEO	6.8yrs
Participación del CEO	2.4%
Permanencia media de la dirección	2.9yrs
Promedio de permanencia en la Junta Directiva	4.1yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Allen Davidoff en comparación con los beneficios de XORTX Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$737k
Jun 30 2024	n/a	n/a	-US$1m
Mar 31 2024	n/a	n/a	-US$3m
Dec 31 2023	US$322k	US$255k	-US$2m
Sep 30 2023	n/a	n/a	-US$7m
Jun 30 2023	n/a	n/a	-US$7m
Mar 31 2023	n/a	n/a	-US$7m
Dec 31 2022	US$321k	US$273k	-US$8m
Sep 30 2022	n/a	n/a	US$1m
Jun 30 2022	n/a	n/a	-US$3m
Mar 31 2022	n/a	n/a	-US$2m
Jan 01 2022	n/a	n/a	-US$2m
Sep 30 2021	n/a	n/a	-US$9m
Jun 30 2021	n/a	n/a	-US$3m
Mar 31 2021	n/a	n/a	-US$3m
Dec 31 2020	US$204k	US$154k	-US$1m
Sep 30 2020	n/a	n/a	-US$767k
Jun 30 2020	n/a	n/a	-US$536k
Mar 31 2020	n/a	n/a	-US$362k
Dec 31 2019	US$161k	US$148k	-US$485k
Sep 30 2019	n/a	n/a	-US$444k
Jun 30 2019	n/a	n/a	-US$582k
Mar 31 2019	n/a	n/a	-US$660k
Dec 31 2018	US$194k	US$141k	-US$3m

Compensación vs. Mercado: La compensación total de Allen($USD321.96K) está por debajo de la media de empresas de tamaño similar en el mercado German ($USD471.55K).

Compensación vs. Ingresos: La compensación de Allen ha aumentado mientras la empresa no es rentable.

CEO

Allen Davidoff (64 yo)

6.8yrs

Permanencia

US$321,959

Compensación

Dr. Allen Warren Davidoff, Ph.D. is Founder of XORTX Therapeutics Inc. (formerly known as XORTX Pharma Corp.) and has been its Chief Executive Officer and President since January 9, 2018. Dr. Davidoff serv...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Allen Davidoff	Founder	6.8yrs	US$321.96k	2.37% € 91.0k
James Fairbairn	Chief Financial Officer	1.4yrs	US$57.51k	0.22% € 8.3k
Stephen Haworth	Chief Medical Officer	3.3yrs	US$173.37k	0% € 0
Stacy Evans	Chief Business Officer	2yrs	US$211.33k	sin datos
Nick Rigopoulos	Director of Communications	no data	sin datos	sin datos
David Sans	Director of Corporate Development	4.3yrs	sin datos	sin datos
David MacDonald	Consultant of Clinical Operations	2.5yrs	sin datos	sin datos
Charlotte May	Corporate Secretary	no data	sin datos	sin datos

2.9yrs

Permanencia media

60.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ANUA se considera experimentado (2.9 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Allen Davidoff	Founder	6.8yrs	US$321.96k	2.37% € 91.0k
Paul Van Damme	Independent Director	6.8yrs	US$8.20k	0.22% € 8.5k
Anthony Giovinazzo	Independent Chair of the Board	2.4yrs	US$101.11k	0.30% € 11.4k
Richard Johnson	Member of Clinical Advisory Board	no data	sin datos	sin datos
William Farley	Independent Director	3.5yrs	US$7.87k	0% € 0
Raymond Pratt	Independent Director	2.9yrs	US$7.37k	0% € 0
Henk E. D. ter Keurs	Member of Scientific Advisory Board	no data	sin datos	sin datos
Federico Maese	Member of Clinical Advisory Board	6.1yrs	sin datos	sin datos
Patrick Treanor	Independent Director	less than a year	sin datos	0% € 0
Petter Bjornstad	Member of Clinical Advisory Board	6.1yrs	sin datos	sin datos
Anjay Rastogi	Member of the Clinical Advisory Board	4.7yrs	sin datos	sin datos
Charles Edelstein	Member of the Advisory Board	3.3yrs	sin datos	sin datos

4.1yrs

Permanencia media

68.5yo

Promedio de edad

Junta con experiencia: La junta directiva de ANUA se considera experimentada (4.1 años de antigüedad promedio).

XORTX Therapeutics Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

XORTX Therapeutics Inc. Appoints Abigail Jenkins to the Board of Directors

XORTX Therapeutics Inc. Appoints Ronald Perrone as Clinical Advisory Board

High number of new and inexperienced directors

XORTX Therapeutics Inc. Announces Board Changes

XORTX Therapeutics Inc. Announces Chief Financial Officer Changes

XORTX Therapeutics Inc. Announces Departure of Jacqueline Le Saux

Recent updates

New major risk - Shareholder dilution

XORTX Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $1.499994 million.

XORTX Therapeutics Inc. Initiates Precision Medicine Program

XORTX Therapeutics Inc. announced delayed 20-F filing

XORTX Therapeutics Inc. Appoints Abigail Jenkins to the Board of Directors

XORTX Therapeutics Inc. Appoints Ronald Perrone as Clinical Advisory Board

XORTX Therapeutics Inc. announced a financing transaction

High number of new and inexperienced directors

XORTX Therapeutics Inc. Announces Board Changes

XORTX Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $3.701931 million.

New major risk - Revenue and earnings growth

XORTX Therapeutics Inc. Announces Presentation of New Research Findings At the American Society of Nephrology Meeting

XORTX Therapeutics to Consider A Consolidation of the Company’s Issued and Outstanding Shares in Order for the Company to Regain Compliance with the Continued Listing Requirements for the Nasdaq Capital Market

XORTX Therapeutics Provides Nasdaq Compliance Update

Xortx Therapeutics Inc. Submits Orphan Drug Designation Application to the European Medicines Agency to Treat Progressive Kidney Disease

XORTX Therapeutics Inc. Announces Chief Financial Officer Changes

XORTX Therapeutics Inc. Announces Departure of Jacqueline Le Saux

XORTX Therapeutics Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency

XORTX Therapeutics Inc. Announces FDA Confirms Eligibility of XORLO™ for Accelerated Approval

XORTX Therapeutics Inc. Announces Goals for 2023

Xortx Therapeutics Inc. Announces Submission of Orphan Drug Designation Request for Xrx-008 Program to Treat Autosomal Dominant Kidney Disease

XORTX Therapeutics Inc. Announces Positive Topline Results from XRX-OXY-101 Clinical Trial

Investor sentiment improved over the past week

XORTX Therapeutics Inc Files New Provisional Patent to Diagnose and Treat Individuals Most at Risk of Polycystic Kidney Disease Progression

XORTX Therapeutics Inc. Announces Completion of Dosing in XRX-OXY-101 Clinical Study

XORTX Therapeutics Inc. Announces New Proof of Concept Data in Autosomal Dominant Polycystic Kidney Disease

XORTX Announces Completion of Screening and Enrollment in Bridging Pharmacokinetics Study

XORTX Therapeutics Appoints Stacy Evans as Chief Business Officer

High number of new and inexperienced directors

XORTX Therapeutics Inc. Receives Further No Objection Letter from Health Canada

XORTX Therapeutics Inc. has completed a Composite Units Offering in the amount of $4.99964 million.

XORTX Therapeutics Inc. Completes Positive Pre-Phase 3 Meeting with the US Food and Drug Administration

XORTX Therapeutics Inc. Announces Positive Topline Results from Part 2 Pharmacokinetics Bridging Study

High number of new and inexperienced directors

XORTX Therapeutics Inc. Announces Submission to European Medicines Agency

XORTX Therapeutics Inc. Announces Positive Topline Results from Pharmacokinetics Bridging Clinical Trial

XORTX Announces Pre-Phase 3 Meeting Request with US Food and Drug Administration (FDA)

XORTX Therapeutics Inc. Appoints Anthony Giovinazzo to the Board of Directors and as Chair of the Board

XORTX Therapeutics Inc., Annual General Meeting, Jul 20, 2022

XORTX Therapeutics Inc. Opens an IND for XRx-008 Program for Autosomal Dominant Polycystic Kidney Disease

XORTX Therapeutics Inc. Initiates Dosing of Human Subjects in the Xrx-Oxy-101 Clinical Trial

XORTX Therapeutics Inc. announced delayed 20-F filing

High number of new and inexperienced directors

XORTX Therapeutics Inc. Receives No Objection Letter from Health Canada

XORTX Therapeutics Inc. Announces Grant of US Patent

Xortx Therapeutics Inc. Announces Filing of an Investigational New Drug Application with the Unites States Food and Drug Administration

XORTX Therapeutics Inc. Provides Corporate Update for 2022

XORTX Therapeutics Announces Filing of Provision Patent for Polycystic Kidney Disease

XORTX Therapeutics Inc. Announces Publication of Mt. Sinai Study of Hospitalized COVID-19 Patients

XORTX Therapeutics Inc., Annual General Meeting, Apr 29, 2021

XORTX Therapeutics Inc. Announces the Filing of A New Provisional Patent Application Entitled "Compositions and Methods for Enhancing Anti-Viral Therapies"

New 90-day high: €0.25

XORTX Therapeutics Inc. announced that it has received CAD 6.121572 million in funding

New 90-day high: €0.22

New 90-day high: €0.20

XORTX Therapeutics Inc. announced that it expects to receive CAD 3 million in funding

XORTX Announces Grant of European Patent

XORTX Therapeutics Inc. Announces Topline Results from Mount Sinai’s COVID-19 Clinical Study

XORTX Therapeutics Inc. Receives Positive Feedback from FDA on COVID-19 Related Acute Kidney Injury

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad